Skip to main content

Test Price

2,000 AED

✅ Home Collection Available

Targeted Mutation Analysis (2 Mutations) in UAE | 2000 AED | 2026 DHA Guidelines

تحليل الطفرات المستهدفة (طفرة 2) في الإمارات | 2000 درهم | معتمد من هيئة الصحة بدبي

Trust Grade A ISO 9001:2015 DHA Licensed
DHA
MOHAP
APPROVED
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
ضمان الدقة: حساسية تشخيصية 99.9% من خلال معالجة معتمدة بموجب ISO.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM – 11 PM).
خدمات لوجستية متميزة: جمع منزلي بمستوى المستشفى عبر سلسلة تبريد معتمدة ISO وخدمة سحب الدم المتنقلة VIP.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counsellors.
إرشادات سريرية: استشارة هاتفية بعد الفحص لتفسير النتائج من مستشارين وراثيين مرخصين من هيئة الصحة بدبي.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – instant confirmation before collection.
التأمين: التحقق من التغطية التأمينية عبر واتساب +971 54 548 8731 قبل موعد السحب.

Test Overview

Targeted Mutation Analysis (2 Mutations) identifies two precisely designated gene variants using the gold‑standard Sanger sequencing method, providing definitive answers for hereditary cancer syndromes, prenatal diagnosis, and rheumatologic predisposition.

تحليل الطفرات المستهدفة (طفرة 2) يحدد بدقة طفرتين جينيتين محددتين باستخدام تقنية تسلسل سانغر المعيارية الذهبية، مما يوفر إجابات قاطعة حول المتلازمات السرطانية الوراثية والتشخيص قبل الولادة والقابلية الروماتيزمية.

Feature Our UAE Advanced Test Closest Alternative
Methodology Sanger Sequencing (Gold Standard, single‑base resolution) NGS panels (lower per‑variant depth)
Diagnostic Sensitivity 99.9% for targeted mutations 89–95% (may miss rare SNVs)
Turnaround Time 10–15 days from collection 3–4 weeks
Sample Types Peripheral blood, plasma, serum, amniotic fluid, cord blood, chorionic villi Often limited to blood/saliva
Accreditation ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), DHA‑MOHAP licensed Varies, may be unaccredited

Physician Insight & Safety Protocol

A note from Dr. PRABHAKAR REDDY, DHA License 61713011

“While this targeted analysis delivers near‑absolute certainty for the two mutations tested, it must be interpreted within your full clinical and family history. A negative result does not eliminate all genetic risk, and a positive finding should be discussed with a specialised physician to plan preventive or therapeutic steps.”

“I urge every patient to remember that no laboratory result replaces a comprehensive consultation—correlate these findings with imaging, physical examination, and personal health context.”

Medication Warning

Do not discontinue prescribed medication without consulting your doctor. Genetic test preparation may require temporary pausing of certain supplements; always follow your physician's advice.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria:

  • Active chemotherapy or radiotherapy (must wait 4 weeks post‑treatment)
  • Recent blood transfusion (< 2 weeks prior)
  • Acute infection with high fever
  • Known interfering anticoagulants not suspended (per physician guidance)

Seek Immediate Medical Care if:

  • Severe bleeding or hematoma at collection site
  • Signs of amniotic fluid leakage after invasive prenatal sampling
  • Fever > 38.5°C post amniocentesis
  • Sudden vision changes or numbness (rare embolic event)

UAE Regulatory Compliance

  • Federal Decree‑Law No. 41 of 2024 (Art. 87): All genetic testing performed with informed consent and confidential reporting.
  • CDS Law 2026 (Minors): Parental/guardian consent mandatory; predictive testing for adult‑onset conditions deferred until age 18.
  • UAE PDPL: Genomic data processed under strict data‑protection protocols; reports transmitted only via encrypted channels.
  • ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139): Quality management across all pre‑analytical, analytical and post‑analytical phases.

Frequently Asked Questions

1. What exactly does Targeted Mutation Analysis (2 Mutations) detect and how reliable is it?

It detects the presence or absence of two specific DNA sequence variants using Sanger sequencing, delivering 99.9% analytical sensitivity and specificity.
يكشف هذا الاختبار عن وجود أو غياب طفرتين جينيتين محددتين باستخدام تسلسل سانغر، بدقة تحليلية تبلغ 99.9%.

2. Which specialists typically order this test and for what conditions?

Gynecologists, oncologists, and rheumatologists request it for hereditary breast/ovarian cancer syndromes, prenatal diagnosis, and genetic rheumatic disorders.
يطلب أطباء النساء والتوليد والأورام والروماتيزم هذا الفحص لمتلازمات السرطان الوراثي والتشخيص قبل الولادة واضطرابات الروماتيزم الجينية.

3. How is the sample collected and when will I receive my results?

A blood draw, amniotic fluid, or cord blood sample is taken; results are securely delivered within 10–15 days via encrypted digital report.
يتم سحب عينة دم أو سائل أمنيوسي أو دم الحبل السري، وتصدر النتائج خلال 10–15 يومًا عبر تقرير رقمي مشفر.

Pre‑Test Requirement: A Doctor's prescription is required for this. (Prescription not applicable for surgery, pregnancy cases, or patients planning to travel abroad – self‑referral accepted under DHA guidelines.)

Sample Types: Peripheral blood, plasma, serum, amniotic fluid, cord blood, chorionic villi.

Turnaround Time: 10–15 days from receipt at the ISO‑certified laboratory.

Facility License: 9834453 (DHA/MOHAP) | Support: WhatsApp +971 54 548 8731

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians